Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results
Corvus Pharmaceuticals (NASDAQ:CRVS) reported significant progress in its clinical trials and financial results for Q2 2025. The company's lead drug candidate soquelitinib showed promising results in Phase 1 trials for atopic dermatitis, with cohort 3 achieving a 64.8% mean EASI reduction compared to 34.4% for placebo. The company is advancing multiple clinical programs, including a Phase 3 trial for peripheral T cell lymphoma (PTCL) and collaboration with NIAID for ALPS treatment.
Financially, Corvus strengthened its position with warrant exercises providing $35.7 million in proceeds during Q2, ending the quarter with $74.4 million in cash. The company expects its cash runway to extend into Q4 2026. R&D expenses increased to $7.9 million, up from $4.1 million in Q2 2024, with a net loss of $8.0 million.
Corvus Pharmaceuticals (NASDAQ:CRVS) ha riportato significativi progressi nei suoi trial clinici e risultati finanziari per il secondo trimestre 2025. Il candidato principale soquelitinib ha mostrato risultati promettenti nelle prove di Fase 1 per la dermatite atopica, con il coorte 3 che ha raggiunto una riduzione media dell'EASI del 64,8% rispetto al 34,4% del placebo. L'azienda sta avanzando con diversi programmi clinici, inclusa una sperimentazione di Fase 3 per il linfoma periferico a cellule T (PTCL) e una collaborazione con NIAID per il trattamento dell'ALPS.
Dal punto di vista finanziario, Corvus ha rafforzato la sua posizione con esercizi di warrant che hanno generato 35,7 milioni di dollari di proventi nel secondo trimestre, chiudendo il trimestre con 74,4 milioni di dollari in contanti. L'azienda prevede che la liquidità disponibile durerà fino al quarto trimestre 2026. Le spese per R&S sono aumentate a 7,9 milioni di dollari, rispetto ai 4,1 milioni del secondo trimestre 2024, con una perdita netta di 8,0 milioni di dollari.
Corvus Pharmaceuticals (NASDAQ:CRVS) informó avances significativos en sus ensayos clínicos y resultados financieros para el segundo trimestre de 2025. El principal candidato a medicamento soquelitinib mostró resultados prometedores en los ensayos de Fase 1 para dermatitis atópica, con el cohorte 3 alcanzando una reducción media del EASI del 64,8% en comparación con el 34,4% del placebo. La compañía está avanzando en múltiples programas clínicos, incluyendo un ensayo de Fase 3 para linfoma periférico de células T (PTCL) y una colaboración con NIAID para el tratamiento de ALPS.
En términos financieros, Corvus fortaleció su posición con ejercicios de warrants que aportaron 35,7 millones de dólares en ingresos durante el segundo trimestre, finalizando el trimestre con 74,4 millones de dólares en efectivo. La compañía espera que su liquidez se extienda hasta el cuarto trimestre de 2026. Los gastos en I+D aumentaron a 7,9 millones de dólares, frente a 4,1 millones en el segundo trimestre de 2024, con una pérdida neta de 8,0 millones de dólares.
Corvus Pharmaceuticals (NASDAQ:CRVS)는 2025년 2분기 임상 시험과 재무 결과에서 중요한 진전을 보고했습니다. 회사의 주요 약물 후보인 소퀠리티닙(soquelitinib)은 아토피 피부염에 대한 1상 시험에서 유망한 결과를 보였으며, 3번째 코호트는 평균 EASI 점수를 64.8% 감소시켜 위약의 34.4%에 비해 뛰어난 효과를 나타냈습니다. 회사는 말초 T세포 림프종(PTCL)에 대한 3상 시험과 ALPS 치료를 위한 NIAID와의 협력 등 여러 임상 프로그램을 진행 중입니다.
재무적으로 Corvus는 워런트 행사로 3,570만 달러의 수익을 올리며 2분기를 마감했으며, 현금 보유액은 7,440만 달러에 달했습니다. 회사는 현금 유동성이 2026년 4분기까지 지속될 것으로 예상합니다. 연구개발 비용은 2024년 2분기의 410만 달러에서 790만 달러로 증가했으며, 순손실은 800만 달러였습니다.
Corvus Pharmaceuticals (NASDAQ:CRVS) a annoncé des progrès significatifs dans ses essais cliniques et ses résultats financiers pour le deuxième trimestre 2025. Le principal candidat médicament soquelitinib a montré des résultats prometteurs lors des essais de phase 1 pour la dermatite atopique, avec le groupe 3 atteignant une réduction moyenne de l'EASI de 64,8% contre 34,4% pour le placebo. L'entreprise fait avancer plusieurs programmes cliniques, y compris un essai de phase 3 pour le lymphome périphérique à cellules T (PTCL) et une collaboration avec le NIAID pour le traitement de l'ALPS.
Sur le plan financier, Corvus a renforcé sa position grâce à l'exercice de bons de souscription ayant généré 35,7 millions de dollars au deuxième trimestre, terminant le trimestre avec 74,4 millions de dollars en liquidités. La société prévoit que sa trésorerie couvrira ses besoins jusqu'au quatrième trimestre 2026. Les dépenses en R&D ont augmenté à 7,9 millions de dollars, contre 4,1 millions au T2 2024, avec une perte nette de 8,0 millions de dollars.
Corvus Pharmaceuticals (NASDAQ:CRVS) meldete bedeutende Fortschritte in seinen klinischen Studien und den Finanzergebnissen für das zweite Quartal 2025. Der führende Arzneimittelkandidat soquelitinib zeigte vielversprechende Ergebnisse in Phase-1-Studien bei atopischer Dermatitis, wobei Kohorte 3 eine durchschnittliche EASI-Reduktion von 64,8% im Vergleich zu 34,4% beim Placebo erzielte. Das Unternehmen treibt mehrere klinische Programme voran, darunter eine Phase-3-Studie für peripheres T-Zell-Lymphom (PTCL) sowie eine Zusammenarbeit mit dem NIAID zur Behandlung von ALPS.
Finanziell stärkte Corvus seine Position durch Warrant-Ausübungen, die im zweiten Quartal 35,7 Millionen US-Dollar einbrachten, und schloss das Quartal mit 74,4 Millionen US-Dollar in bar ab. Das Unternehmen erwartet, dass die liquide Mittel bis ins vierte Quartal 2026 reichen. Die F&E-Ausgaben stiegen auf 7,9 Millionen US-Dollar, von 4,1 Millionen im zweiten Quartal 2024, bei einem Nettoverlust von 8,0 Millionen US-Dollar.
- Soquelitinib showed 64.8% mean EASI reduction in cohort 3 vs 34.4% for placebo in atopic dermatitis trial
- Warrant exercises generated $35.7 million in cash proceeds
- Strong cash position of $74.4 million, extending runway into Q4 2026
- FDA granted Orphan Drug Designation and Fast Track designation for soquelitinib in T cell lymphoma
- R&D expenses increased significantly to $7.9 million from $4.1 million year-over-year
- Net loss widened to $8.0 million compared to $4.3 million in Q2 2024
- Non-cash loss of $0.4 million from Angel Pharmaceuticals investment vs. income of $0.6 million last year
Insights
Positive Phase 1 data for Corvus' soquelitinib in atopic dermatitis shows promising efficacy, with expanded trials and a strong cash position to fund operations.
Corvus Pharmaceuticals has reported promising interim results from their Phase 1 trial testing soquelitinib in atopic dermatitis. The 64.8% mean reduction in EASI scores at 28 days in cohort 3 substantially outperformed both earlier cohorts (54.6%) and placebo (34.4%). Particularly noteworthy is the rapid onset of action, with responses seen as early as day 8, and 50% of evaluable patients achieving significant itch reduction versus just 10% on placebo.
The company is executing a methodical dose optimization strategy. Cohort 3's 200mg BID dose is now being tested in an 8-week extension trial, while their Chinese partner Angel Pharmaceuticals plans an even longer 12-week study including a 400mg once-daily regimen. This parallel approach accelerates their clinical timeline while expanding the efficacy dataset.
Beyond dermatology, Corvus is advancing soquelitinib in multiple immune-mediated conditions, highlighting the drug's mechanistic versatility. Their Phase 3 registrational trial in peripheral T-cell lymphoma represents their most advanced program and targets an indication with limited FDA-approved treatment options.
Financially, Corvus has significantly strengthened its position through $35.7 million in warrant exercises, extending their operational runway into Q4 2026. This improved cash position (
The interim data profile of soquelitinib in atopic dermatitis appears competitive with established treatments in this crowded therapeutic landscape, particularly regarding rapid onset of action and itch reduction - outcomes highly valued by patients. The clean safety profile to date further enhances its potential therapeutic value.
Soquelitinib data from cohort 3 of atopic dermatitis Phase 1 clinical trial demonstrates earlier and deeper responses compared to cohorts 1-2 along with clinically meaningful reduction in itch as early as day 8
Enrollment ongoing in Phase 1 trial extension cohort 4 exploring the same cohort 3 dose (200 mg BID) for a longer 8-week treatment period; Phase 2 trial on track to initiate before end of year
Phase 3 registrational clinical trial of soquelitinib in relapsed/refractory peripheral T cell lymphoma (PTCL) enrolling with multiple clinical sites open
Stockholders exercised common stock warrants during the second quarter that provided cash proceeds of
Conference call and webcast today at 4:30 p.m. ET / 1:30 p.m. PT
SOUTH SAN FRANCISCO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the second quarter ended June 30, 2025.
“We are excited by the data reported from our Phase 1 trial of soquelitinib for atopic dermatitis and are advancing its development for this indication on multiple fronts,” said Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus. “This includes patient enrollment in the extension cohort 4 of the Phase 1 trial, which is exploring an 8-week treatment period and is on track to report data in the fourth quarter 2025, along with near-final plans for a Phase 2 trial that we expect to initiate before year-end. In China, our partner Angel Pharmaceuticals plans to initiate a separate Phase 1b/2 trial, which will further expand the clinical experience with soquelitinib, including a 12-week treatment period and a 400 mg once-daily dose. In addition, enrollment continues in our Phase 3 registration clinical trial in PTCL and the Phase 2 trial in autoimmune lymphoproliferative syndrome (ALPS), reflecting the broader opportunity for ITK inhibition across a range of immune diseases.”
Business Update and Strategy
Soquelitinib (Corvus’ selective ITK inhibitor) for Immune Diseases
- On June 4, 2025, Corvus reported interim results (data cutoff date of May 28, 2025) from the first three cohorts of its randomized, placebo-controlled Phase 1 clinical trial of soquelitinib in patients with moderate to severe atopic dermatitis that continued to demonstrate a favorable safety profile and efficacy profile. Patients in cohort 3 had more advanced disease with a higher mean baseline EASI (Eczema Area and Severity Index) score compared to patients in cohorts 1 and 2. At 28 days, the mean reduction in EASI for cohort 3 (n=12) was
64.8% , compared to54.6% for cohort 1 and 2 combined (n=24) and34.4% for placebo (n=12). Cohort 3 patients experienced earlier responses and deeper separation from placebo compared to cohorts 1 and 2 starting by day 8. EASI scores continue to improve further in treated patients from all cohorts out to day 58. - In cohort 3, of the patients for whom adequate PP-NRS (Peak Pruritus Numerical Rating Scale) data was available, 4 of 8 (
50% ) had a ≥4 point reduction in PP-NRS score from baseline at day 28, with a reduction in itch seen as early as day 8. Of the remaining patients, two had baseline PP-NRS of less than 4 and two had incomplete PP-NRS data. One of 10 evaluable placebo patients (10% ) experienced a ≥4 point reduction in PP-NRS score at Day 28. - As of the data cutoff, soquelitinib was well tolerated in the Phase 1 clinical trial, with no dose limiting toxicities (DLTs) and no clinically significant laboratory abnormalities observed in any of the cohorts.
- Corvus initiated enrollment in extension cohort 4 of the Phase 1 clinical trial, which is planned to study 24 patients randomized 1:1 between active (soquelitinib 200 mg twice per day, the same dose as cohort 3) and placebo. The treatment period for this group is 8 weeks, compared to 4 weeks in cohorts 1-3, with the same additional 30-day follow-up period with no treatment.
- Angel Pharmaceuticals, Corvus’ partner in China, has been approved by the Center for Drug Evaluation of the China National Medical Products Administration to initiate a Phase 1b/2 clinical trial of soquelitinib for the treatment of patients with moderate-to-severe atopic dermatitis in China. The trial, which is planned to enroll 48 patients and will study four soquelitinib doses and placebo, will further expand the clinical experience with soquelitinib in atopic dermatitis, including a 12-week treatment period and a 400 mg once-daily dose.
- Preclinical data highlighting the potential of soquelitinib to treat systemic sclerosis was presented in a poster session at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress, where it was selected as a top 10 abstract by the Emerging EULAR Network (EMEUNET), a network of young rheumatologists and researchers in the field of rheumatology in Europe and beyond.
- Corvus also continues to advance its next-generation ITK inhibitor preclinical product candidates, which are designed to deliver precise T-cell modulation that is optimized for specific immunology indications.
Collaboration with National Institute of Allergy and Infectious Diseases (NIAID)
- Patient enrollment continues in the ALPS Phase 2 clinical trial, which is being conducted under a clinical research and development agreement with NIAID. The Phase 2 clinical trial (NCT06730126) is anticipated to enroll up to 30 patients aged 16 or older with confirmed ALPS based on genetic testing.
Soquelitinib for T Cell Lymphoma
- Corvus continues to enroll patients in a registrational Phase 3 clinical trial of soquelitinib in patients with relapsed/refractory PTCL at multiple clinical sites. This randomized controlled trial is anticipated to enroll a total of 150 patients with relapsed/refractory PTCL and is evaluating soquelitinib versus physicians’ choice of either belinostat or pralatrexate. The primary endpoint of the trial is progression free survival. There are no FDA fully approved agents for the treatment of relapsed/refractory PTCL, and the FDA has granted soquelitinib Orphan Drug Designation for the treatment of T cell lymphoma and Fast Track designation for treatment of adult patients with relapsed or refractory PTCL after at least 2 lines of systemic therapy.
Collaboration with Kidney Cancer Research Consortium: Ciforadenant (adenosine A2a receptor inhibitor)
- Corvus is collaborating with the Kidney Cancer Research Consortium (KCRC) in a Phase 1b/2 clinical trial evaluating ciforadenant as a potential first line therapy for metastatic renal cell cancer (RCC) in combination with ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1). The trial is fully enrolled and patients are being followed.
Partner Led Program: Mupadolimab (anti-CD73)
- Angel Pharmaceuticals continues to evaluate data from its Phase 1/1b clinical trial of mupadolimab in patients with relapsed non-small cell lung cancer (NSCLC).
Financial Results
As of June 30, 2025, Corvus had cash, cash equivalents and marketable securities of
Research and development expenses for the three months ended June 30, 2025 totaled
Net loss for the three months ended June 30, 2025 was
Conference Call Details
Corvus will host a conference call and webcast today, Thursday, August 7, 2025, at 4:30 p.m. ET (1:30 p.m. PT), during which time management will provide a business update and discuss the second quarter 2025 financial results. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus’ website for 90 days.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com or follow the Company on LinkedIn.
About Soquelitinib
Soquelitinib (formerly CPI-818) is an investigational small molecule drug given orally designed to selectively inhibit ITK (interleukin-2-inducible T cell kinase), an enzyme that is expressed predominantly in T cells and plays a role in T cell and natural killer (NK) cell immune function. Soquelitinib has been shown to affect T cell differentiation and induce the generation of Th1 helper cells while blocking the development of both Th2 and Th17 cells and production of their secreted cytokines. Th1 T cells are required for immunity to tumors, viral infections and other infectious diseases. Th2 and Th17 helper T cells are involved in the pathogenesis of many autoimmune and allergic diseases. The Company believes the inhibition of specific molecular targets in T cells may be of therapeutic benefit for patients with cancers, including solid tumors, and in patients with autoimmune and allergic diseases. Recent studies have demonstrated that ITK controls a switch between the differentiation of Th17 proinflammatory cells and T regulatory suppressor cells. Inhibition of ITK leads to a shift toward T regulatory cell differentiation which has the potential to suppress autoimmune and inflammatory reactions. Based on interim results from a Phase 1/1b clinical trial in patients with refractory T cell lymphomas, which demonstrated tumor responses in very advanced, refractory, difficult to treat T cell malignancies, the Company has initiated a registrational Phase 3 clinical trial (NCT06561048) of soquelitinib in patients with relapsed/refractory PTCL. Soquelitinib is also now being investigated in a randomized placebo-controlled phase 1 clinical trial in patients with atopic dermatitis. A recent publication describing the chemistry, enzymology and biology of soquelitinib appeared in npj Drug Discovery in December 2024 and is available online at the Nature website and on the Publications and Presentations page of the Corvus website.
About Peripheral T Cell Lymphoma
Peripheral T cell lymphoma is a heterogeneous group of malignancies accounting for about
PTCL is a disease of mature helper T cells that express ITK, often containing numerous genetic mutations and frequently associated with viral infection. Most often the malignant cells of PTCL express a Th2 phenotype.
About Atopic Dermatitis
Atopic dermatitis, also called eczema, is a chronic disease that can cause inflammation, redness, scaly patches, blisters and irritation of the skin. It affects up to
About Autoimmune Lymphoproliferative Syndrome (ALPS)
ALPS is a rare genetic disease affecting children that manifests with lymphadenopathy, splenomegaly, cytopenias (low blood counts), proteinuria and autoimmunity. The disease is caused by a mutation in the Fas gene, which provides instructions for making a signaling protein involved in the induction of apoptosis. The mutation results in immune dysregulation due to abnormally high levels of “double negative” T cells (CD4 and CD8 double negative), which infiltrate the blood, spleen and lymphoid tissues. Fas signaling is regulated by ITK and T cell receptor signaling and patients with ALPS have an imbalance in this regulation resulting in a failure of T cells to undergo apoptosis and an accumulation of abnormal T cells.
About Ciforadenant
Ciforadenant (CPI-444) is an investigational small molecule, oral, checkpoint inhibitor designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of adenosine to immune cells present in the tumor microenvironment. Adenosine, a metabolite of ATP (adenosine tri-phosphate), is produced within the tumor microenvironment where it may bind to the adenosine A2a receptor present on immune cells and block their activity. Ciforadenant has been shown to block the immunosuppressive effects of myeloid cells present in tumors and preclinical studies published in 2018 demonstrated synergy with combinations of anti PD1 and anti-CTLA4 antibodies.
About Mupadolimab
Mupadolimab (CPI-006) is an investigational, potent humanized monoclonal antibody that is designed to react with a specific site on CD73. In preclinical studies, it has demonstrated immunomodulatory activity resulting in activation of lymphocytes, induction of antibody production from B cells and effects on lymphocyte trafficking. Unlike certain other anti-CD73 antibodies and small molecules in development for treatment of cancer, which react with a different region of CD73, mupadolimab is designed to react with a region of the molecule that acts to stimulate B cells and block production of immunosuppressive adenosine. It is postulated that the activation of B cells will enhance immunity within the tumors, leading to improved clinical outcomes.
About Angel Pharmaceuticals
Angel Pharmaceuticals is a privately held biopharmaceutical company developing a pipeline of precisely targeted investigational medicines for cancer, autoimmune, infectious and other serious diseases in China. Angel Pharmaceuticals was launched through a collaboration with Corvus and investments from investors in China. Angel Pharmaceuticals licensed the rights to develop and commercialize Corvus’ three clinical-stage candidates – soquelitinib, ciforadenant and mupadolimab – in greater China and obtained global rights to Corvus’ BTK inhibitor preclinical programs. Under the collaboration, Corvus currently has a
Forward-Looking Statements
This press release contains forward-looking statements, including statements related to the potential safety and efficacy of the Company’s product candidates; the interim results from the Phase 1 trial of soquelitinib in patients with atopic dermatitis; the potential use of soquelitinib to treat a variety of hematological cancers and autoimmune diseases; clinical strategy and the design of clinical trials, including the timeline for initiation, target or expected number of patients to be enrolled, dose levels, number of sites and other product development milestones; the availability and timing of clinical and preclinical data announcements and clinical readouts, including data from the extension cohort of the Phase 1 clinical trial for atopic dermatitis with soquelitinib; and the amount of cash to fund operations into the fourth quarter of 2026. All statements other than statements of historical fact contained in this press release are forward-looking statements. These statements often include words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “seek,” “will,” “may” or similar expressions. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company’s control. The Company’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in the Company’s Quarterly Report on Form 10-Q for the second quarter ended June 30, 2025, filed with the Securities and Exchange Commission on or about the date hereof, as well as other documents that may be filed by the Company from time to time with the Securities and Exchange Commission. In particular, the following factors, among others, could cause results to differ materially from those expressed or implied by such forward-looking statements: the Company’s ability to demonstrate sufficient evidence of efficacy and safety in its clinical trials of its product candidates; the accuracy of the Company’s estimates relating to its ability to initiate and/or complete preclinical studies and clinical trials and release data from such studies and clinical trials; the results of preclinical studies and interim data from clinical trials not being predictive of future results; the Company’s ability to enroll sufficient numbers of patients in its clinical trials; the unpredictability of the regulatory process; regulatory developments in the United States and foreign countries; the costs of clinical trials may exceed expectations; the Company’s ability to accurately estimate the cash on hand providing funding into the fourth quarter of 2026 and the Company’s ability to raise additional capital. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the events and circumstances reflected in the forward-looking statements will be achieved or occur, and the timing of events and circumstances and actual results could differ materially from those projected in the forward-looking statements. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. The Company’s results for the second quarter ended June 30, 2025 are not necessarily indicative of its operating results for any future periods.
| CORVUS PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except share and per share data) | |||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||
| (unaudited) | (unaudited) | ||||||||||||||
| Operating expenses: | |||||||||||||||
| Research and development | $ | 7,873 | $ | 4,114 | $ | 15,326 | $ | 8,189 | |||||||
| General and administrative | 2,387 | 1,821 | 4,856 | 3,999 | |||||||||||
| Total operating expenses | 10,260 | 5,935 | 20,182 | 12,188 | |||||||||||
| Loss from operations | (10,260 | ) | (5,935 | ) | (20,182 | ) | (12,188 | ) | |||||||
| Interest income and other expense, net | 639 | 434 | 1,164 | 750 | |||||||||||
| Change in fair value of warrant liability | 2,012 | 1,816 | 27,141 | 1,816 | |||||||||||
| Income (loss) before equity method investment | (7,609 | ) | (3,685 | ) | 8,123 | (9,622 | ) | ||||||||
| Loss from equity method investment | (389 | ) | (577 | ) | (928 | ) | (341 | ) | |||||||
| Net income (loss) | $ | (7,998 | ) | $ | (4,262 | ) | $ | 7,195 | $ | (9,963 | ) | ||||
| Net income (loss) per share, basic | $ | (0.10 | ) | $ | (0.07 | ) | $ | 0.10 | $ | (0.18 | ) | ||||
| Net loss per share, diluted | $ | (0.10 | ) | $ | (0.07 | ) | $ | (0.26 | ) | $ | (0.18 | ) | |||
| Shares used to compute net income (loss) per share, basic | 77,774,344 | 59,710,265 | 74,966,022 | 54,374,423 | |||||||||||
| Shares used to compute net loss per share, diluted | 77,774,344 | 59,710,265 | 76,521,708 | 54,374,423 | |||||||||||
| CORVUS PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands) | |||||||
| June 30, | December 31, | ||||||
| 2025 | 2024 | ||||||
| (unaudited) | |||||||
| Assets | |||||||
| Cash, cash equivalents and marketable securities | $ | 74,407 | $ | 51,964 | |||
| Operating lease right-of-use asset | 1,012 | 1,177 | |||||
| Other assets | 2,248 | 3,226 | |||||
| Investment in Angel Pharmaceuticals | 11,794 | 12,540 | |||||
| Total assets | $ | 89,461 | $ | 68,907 | |||
| Liabilities and stockholders' equity | |||||||
| Accounts payable and accrued liabilities and other liabilities | $ | 8,150 | $ | 6,307 | |||
| Operating lease liability | 1,083 | 1,122 | |||||
| Warrant liability | - | 28,910 | |||||
| Stockholders' equity | 80,228 | 32,568 | |||||
| Total liabilities and stockholders' equity | $ | 89,461 | $ | 68,907 | |||
INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
llea@corvuspharma.com
MEDIA CONTACT:
Sheryl Seapy
Real Chemistry
+1-949-903-4750
sseapy@realchemistry.com
FAQ
What were the key clinical trial results for Corvus' soquelitinib in atopic dermatitis?
How much cash does Corvus Pharmaceuticals (CRVS) have and what is their cash runway?
What was Corvus Pharmaceuticals' (CRVS) net loss in Q2 2025?
What regulatory designations has soquelitinib received from the FDA?
What are the next steps for Corvus' soquelitinib development program?
